Armodafinil

This review summarizes healthy-volunteer work showing that armodafinil improves wakefulness and sustained attention during sleep loss. It supports the interpretation that armodafinil's main healthy-subject benefit is alertness rather than broad cognitive enhancement.

This review reports that armodafinil improved wakefulness and sustained attention in healthy subjects, with effects lasting into the later part of the day. It also notes that the magnitude of benefit was modest and most apparent on vigilance-type tasks.

In 107 healthy men, single doses of armodafinil improved wakefulness and sustained attention versus placebo. Common adverse effects included abdominal pain, nausea, headache, and reports of tachycardia or palpitations, with small increases in blood pressure and reduced sleep efficiency.

This review summarizes healthy-volunteer work showing that armodafinil improves wakefulness and sustained attention during sleep loss. It supports the interpretation that armodafinil's main healthy-subject benefit is alertness rather than broad cognitive enhancement.

This review reports that armodafinil improved wakefulness and sustained attention in healthy subjects, with effects lasting into the later part of the day. It also notes that the magnitude of benefit was modest and most apparent on vigilance-type tasks.

In 107 healthy men, single doses of armodafinil improved wakefulness and sustained attention versus placebo. Common adverse effects included abdominal pain, nausea, headache, and reports of tachycardia or palpitations, with small increases in blood pressure and reduced sleep efficiency.

This review summarizes healthy-volunteer work showing that armodafinil improves wakefulness and sustained attention during sleep loss. It supports the interpretation that armodafinil's main healthy-subject benefit is alertness rather than broad cognitive enhancement.

This review reports that armodafinil improved wakefulness and sustained attention in healthy subjects, with effects lasting into the later part of the day. It also notes that the magnitude of benefit was modest and most apparent on vigilance-type tasks.

In 107 healthy men, single doses of armodafinil improved wakefulness and sustained attention versus placebo. Common adverse effects included abdominal pain, nausea, headache, and reports of tachycardia or palpitations, with small increases in blood pressure and reduced sleep efficiency.

This review summarizes healthy-volunteer work showing that armodafinil improves wakefulness and sustained attention during sleep loss. It supports the interpretation that armodafinil's main healthy-subject benefit is alertness rather than broad cognitive enhancement.

This review reports that armodafinil improved wakefulness and sustained attention in healthy subjects, with effects lasting into the later part of the day. It also notes that the magnitude of benefit was modest and most apparent on vigilance-type tasks.

In 107 healthy men, single doses of armodafinil improved wakefulness and sustained attention versus placebo. Common adverse effects included abdominal pain, nausea, headache, and reports of tachycardia or palpitations, with small increases in blood pressure and reduced sleep efficiency.

This review reports that armodafinil improved wakefulness and sustained attention in healthy subjects, with effects lasting into the later part of the day. It also notes that the magnitude of benefit was modest and most apparent on vigilance-type tasks.

This review summarizes healthy-volunteer work showing that armodafinil improves wakefulness and sustained attention during sleep loss. It supports the interpretation that armodafinil's main healthy-subject benefit is alertness rather than broad cognitive enhancement.

In 107 healthy men, single doses of armodafinil improved wakefulness and sustained attention versus placebo. Common adverse effects included abdominal pain, nausea, headache, and reports of tachycardia or palpitations, with small increases in blood pressure and reduced sleep efficiency.

In 119 healthy subjects, armodafinil showed linear pharmacokinetics over 50 to 400 mg and was generally well tolerated. Headache, dizziness, and nausea were the most frequent adverse effects, and food delayed peak concentration without changing overall exposure.

In 107 healthy men, single doses of armodafinil improved wakefulness and sustained attention versus placebo. Common adverse effects included abdominal pain, nausea, headache, and reports of tachycardia or palpitations, with small increases in blood pressure and reduced sleep efficiency.

This review summarizes healthy-volunteer work showing that armodafinil improves wakefulness and sustained attention during sleep loss. It supports the interpretation that armodafinil's main healthy-subject benefit is alertness rather than broad cognitive enhancement.

In 107 healthy men, single doses of armodafinil improved wakefulness and sustained attention versus placebo. Common adverse effects included abdominal pain, nausea, headache, and reports of tachycardia or palpitations, with small increases in blood pressure and reduced sleep efficiency.

In 119 healthy subjects, armodafinil showed linear pharmacokinetics over 50 to 400 mg and was generally well tolerated. Headache, dizziness, and nausea were the most frequent adverse effects, and food delayed peak concentration without changing overall exposure.

In 107 healthy men, single doses of armodafinil improved wakefulness and sustained attention versus placebo. Common adverse effects included abdominal pain, nausea, headache, and reports of tachycardia or palpitations, with small increases in blood pressure and reduced sleep efficiency.

In 119 healthy subjects, armodafinil showed linear pharmacokinetics over 50 to 400 mg and was generally well tolerated. Headache, dizziness, and nausea were the most frequent adverse effects, and food delayed peak concentration without changing overall exposure.

In 107 healthy men, single doses of armodafinil improved wakefulness and sustained attention versus placebo. Common adverse effects included abdominal pain, nausea, headache, and reports of tachycardia or palpitations, with small increases in blood pressure and reduced sleep efficiency.

In 107 healthy men, single doses of armodafinil improved wakefulness and sustained attention versus placebo. Common adverse effects included abdominal pain, nausea, headache, and reports of tachycardia or palpitations, with small increases in blood pressure and reduced sleep efficiency.

In 107 healthy men, single doses of armodafinil improved wakefulness and sustained attention versus placebo. Common adverse effects included abdominal pain, nausea, headache, and reports of tachycardia or palpitations, with small increases in blood pressure and reduced sleep efficiency.

In 107 healthy men, single doses of armodafinil improved wakefulness and sustained attention versus placebo. Common adverse effects included abdominal pain, nausea, headache, and reports of tachycardia or palpitations, with small increases in blood pressure and reduced sleep efficiency.

After 7 days of 200 mg daily in healthy Chinese subjects, armodafinil was generally safe with no serious adverse events. Fever occurred in several participants, showing that uncommon systemic side effects can occur during repeated dosing.